These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26270243)

  • 1. Angiogenic characteristics of blood outgrowth endothelial cells from patients with von Willebrand disease.
    Groeneveld DJ; van Bekkum T; Dirven RJ; Wang JW; Voorberg J; Reitsma PH; Eikenboom J
    J Thromb Haemost; 2015 Oct; 13(10):1854-66. PubMed ID: 26270243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients.
    Selvam SN; Casey LJ; Bowman ML; Hawke LG; Longmore AJ; Mewburn J; Ormiston ML; Archer SL; Maurice DH; James P
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):521-533. PubMed ID: 28362648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease.
    Wang JW; Bouwens EA; Pintao MC; Voorberg J; Safdar H; Valentijn KM; de Boer HC; Mertens K; Reitsma PH; Eikenboom J
    Blood; 2013 Apr; 121(14):2762-72. PubMed ID: 23426949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.
    Bowman ML; Pluthero FG; Tuttle A; Casey L; Li L; Christensen H; Robinson KS; Lillicrap D; Kahr WHA; James P
    J Thromb Haemost; 2017 Jul; 15(7):1403-1411. PubMed ID: 28453889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.
    Starke RD; Paschalaki KE; Dyer CE; Harrison-Lavoie KJ; Cutler JA; McKinnon TA; Millar CM; Cutler DF; Laffan MA; Randi AM
    Blood; 2013 Apr; 121(14):2773-84. PubMed ID: 23355534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.
    De Meyer SF; Vanhoorelbeke K; Chuah MK; Pareyn I; Gillijns V; Hebbel RP; Collen D; Deckmyn H; VandenDriessche T
    Blood; 2006 Jun; 107(12):4728-36. PubMed ID: 16478886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor regulation of blood vessel formation.
    Randi AM; Smith KE; Castaman G
    Blood; 2018 Jul; 132(2):132-140. PubMed ID: 29866817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study.
    Groeneveld DJ; Sanders YV; Adelmeijer J; Mauser-Bunschoten EP; van der Bom JG; Cnossen MH; Fijnvandraat K; Laros-van Gorkom BAP; Meijer K; Lisman T; Eikenboom J; Leebeek FWG
    Thromb Haemost; 2018 Jan; 118(1):152-160. PubMed ID: 29304535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.
    Berber E; James PD; Hough C; Lillicrap D
    J Thromb Haemost; 2009 Oct; 7(10):1672-9. PubMed ID: 19624459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial von Willebrand factor regulates angiogenesis.
    Starke RD; Ferraro F; Paschalaki KE; Dryden NH; McKinnon TA; Sutton RE; Payne EM; Haskard DO; Hughes AD; Cutler DF; Laffan MA; Randi AM
    Blood; 2011 Jan; 117(3):1071-80. PubMed ID: 21048155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor.
    de Jong A; Dirven RJ; Oud JA; Tio D; van Vlijmen BJM; Eikenboom J
    J Thromb Haemost; 2018 Jul; 16(7):1357-1368. PubMed ID: 29734512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of genetic testing for the diagnosis of von Willebrand disease.
    Seidizadeh O; Baronciani L; Lillicrap D; Peyvandi F
    J Thromb Haemost; 2024 Aug; 22(8):2115-2128. PubMed ID: 38762018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
    Sztukowska M; Gallinaro L; Cattini MG; Pontara E; Sartorello F; Daidone V; Padrini R; Pagnan A; Casonato A
    Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype.
    Castaman G; Giacomelli SH; Jacobi P; Obser T; Budde U; Rodeghiero F; Haberichter SL; Schneppenheim R
    J Thromb Haemost; 2010 Sep; 8(9):2011-6. PubMed ID: 20586924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
    Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
    J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.